{"id":26121,"date":"2026-03-17T10:38:39","date_gmt":"2026-03-17T14:38:39","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=26121"},"modified":"2026-03-17T10:38:39","modified_gmt":"2026-03-17T14:38:39","slug":"emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/sv\/emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer\/","title":{"rendered":"Emily\u2019s Entourage Appoints David A. Waltz, MD, as First Chief Medical Officer"},"content":{"rendered":"

Veteran cystic fibrosis physician-scientist and former Vertex Pharmaceuticals senior leader to help accelerate therapies for the final 10% of people with cystic fibrosis<\/span><\/i><\/p>\n

\"\"Philadelphia, PA\u2014March 17, 2026<\/b>-<\/span>Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating new treatments and a cure for the final 10% of people with cystic fibrosis (CF) that do not benefit from existing CFTR modulator therapies<\/span>, today announced the appointment of David A. Waltz, MD, as the organization\u2019s first Chief Medical Officer (CMO).<\/span><\/p>\n

In this inaugural role\u2014an important milestone reflecting EE\u2019s growth and deepening investment in CF therapeutic development\u2014Dr. Waltz will work closely with Chief Scientific Officer, Chandra Ghose, PhD, to bolster EE\u2019s research and therapeutic development strategy and help propel promising discoveries funded by the organization from early scientific insight toward clinical development, positioning EE for the next era of breakthrough treatments.<\/span><\/p>\n

An industry leader whose career spans academic medicine, translational science, and clinical research in the biotech and pharmaceutical industries, Dr. Waltz most recently served as Vice President and Head of Cystic Fibrosis Clinical Development at Vertex Pharmaceuticals Inc., where he led the advancement of transformative CFTR modulators, including combination therapies that have reshaped the treatment landscape for roughly 90% of people with CF.<\/span><\/p>\n

\u201cAs Emily\u2019s Entourage continues to expand our research portfolio and push toward the next generation of treatments, bringing on our first Chief Medical Officer marks a monumental step forward for our mission,\u201d said Emily Kramer-Golinkoff, MBE, Co-Founder of EE.\u00a0<\/span><\/p>\n

\u201cFor the final 10% of the CF community that do not benefit from existing CFTR modulator therapies, time matters. Dr. Waltz brings extraordinary experience turning scientific discoveries into lifesaving medicines. His leadership will help advance promising therapies into the clinical space quickly.\u201d\u00a0\u00a0<\/span><\/p>\n

Dr. Waltz began his career as a pediatric pulmonologist and physician-scientist at Boston Children\u2019s Hospital and Harvard Medical School, where he treated people with CF and led clinical research initiatives. He later transitioned to industry leadership roles at Novartis Institutes for BioMedical Research and Vertex Pharmaceuticals, where he played a central role in advancing multiple CF therapies through clinical development and regulatory approval.<\/span><\/p>\n

At EE, he will help guide the organization\u2019s growing research investments with a particular focus on translational medicine\u2014ensuring that promising discoveries move efficiently from the laboratory toward clinical trials and ultimately to people with CF in the final 10%.<\/span><\/p>\n

\u201cEmily\u2019s Entourage has created an extraordinary engine for innovative CF research with a relentless focus on delivering meaningful progress for the members of the community who have long been left behind,\u201d said Dr. Waltz. \u201cI\u2019m honored to join this mission and help accelerate the translation of groundbreaking science into therapies with the power to transform lives for the individuals and families still waiting.\u201d<\/span><\/p>\n

In addition to advising on research and clinical development strategy, Dr. Waltz will serve as a key outward-facing scientific leader for EE, strengthening collaborations across academia, industry, and the broader CF community. He will represent EE at scientific forums and apply his clinical and regulatory expertise to help identify and advance new therapeutic opportunities emerging from EE\u2019s research portfolio.<\/span><\/p>\n

Om Emily's Entourage<\/b><\/p>\n

Emily's Entourage \u00e4r en innovativ 501(c)3 som p\u00e5skyndar forskning f\u00f6r nya behandlingar och ett botemedel f\u00f6r individer i den sista 10% av cystisk fibros (CF)-populationen som inte drar nytta av de mutationsinriktade terapier som f\u00f6r n\u00e4rvarande finns tillg\u00e4ngliga. Sedan 2011 har Emily's Entourage beviljat miljontals dollar i forskningsanslag, lanserat ett genterapibolag f\u00f6r CF i klinisk fas, utvecklat en global patientdatabas och ett matchningsprogram f\u00f6r kliniska pr\u00f6vningar f\u00f6r att p\u00e5skynda rekryteringen till kliniska pr\u00f6vningar samt lett globala insatser f\u00f6r att driva forskning och l\u00e4kemedelsutveckling med stor genomslagskraft. Organisationen har uppm\u00e4rksammats i nationell media, bland annat i New York Times, STAT, CNN, People med flera. L\u00e4s mer p\u00e5 <\/span>emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Kontakt med media<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Direkt\u00f6r f\u00f6r marknadsf\u00f6ring och kommunikation<\/span><\/p>\n

hannah@emilysentourage.org<\/span><\/p>\n

###<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Veteran cystic fibrosis physician-scientist and former Vertex Pharmaceuticals senior leader to help accelerate therapies for the final 10% of people with cystic fibrosis Philadelphia, PA\u2014March 17, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating new treatments and a cure for the final 10% of people with cystic fibrosis (CF) that do not benefit from existing… <\/p>\n

<\/div>\n

L\u00e4s mer om<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[178],"tags":[197,217,265,7,267,266],"class_list":["post-26121","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-chief-medical-officer","tag-cystic-fibrosis","tag-ee-cmo","tag-ee-staff"],"acf":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/posts\/26121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/comments?post=26121"}],"version-history":[{"count":2,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/posts\/26121\/revisions"}],"predecessor-version":[{"id":26125,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/posts\/26121\/revisions\/26125"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/media?parent=26121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/categories?post=26121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/sv\/wp-json\/wp\/v2\/tags?post=26121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}